Coronavirus: why antibody tests may miss a quarter of cases
New research suggests ‘game-changing’ tests bought by UK government may be less accurate than previously thought
A test for Covid-19 antibodies that health officials have described as “100% accurate” may be giving incorrect results for as many as a quarter of people who have had the virus, an independent analysis suggests.
The UK government ordered ten million of the tests, made by Swiss company Roche, last month after Public Health England (PHE) vouched for their accuracy.
“However, an independent scientific evaluation of the PHE tests has raised concerns about the methods used to assess them and how well they are likely to work,” The Times reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Why are antibody tests important?
As far back as March, Boris Johnson was describing the prospect of a reliable test for Covid-19 antibodies as a game changer.
“The great thing about having a test to see whether you’ve had it,” he said, “is suddenly a green light goes on above your head and you can go back to work safe and confident in the knowledge that you are most unlikely to get it again”.
However, scientists have been more cautious. “If you test positive for antibodies, it’s likely you have a degree of immunity,” Dr Ron Daniels of University Hospitals Birmingham NHS Foundation Trust told The Telegraph.
“We’re not sure for how long, and how much, so you shouldn’t stop [social] distancing, but best guess it is likely to be partially protective for at least a few months.”
What were the findings of the PHE research?
“It was widely reported in May that a new antibody test - which can detect if someone has had Covid-19 - is ‘100% accurate’,” says fact-checking website Full Fact. “However, this is not quite correct.”
After carrying out an evaluation in government science labs at Porton Down, PHE concluded that the Roche tests had “100% specificity, which means it accurately identified all negative samples as negative”, says Sky News.
This is important, as it means no one will be told they have immunity when they don’t.
Where the test was less successful was in its “sensitivity” - which refers to detecting positive cases. “It missed 16% of the samples of people who had Covid-19,” Sky News reports.
And the conclusions of the new analysis?
A review by the Test Evaluation Research Group at the University of Birmingham found that the small sample size used in the Porton Down validation tests has resulted in a significant margin of error. “This could mean that the test may miss between 8% and 25% of actual past Covid infections,” says The Times.
More encouragingly, the review did not find any evidence of false positives.
–––––���–––––––––––––––––––––––––For a round-up of the most important stories from around the world - and a concise, refreshing and balanced take on the week’s news agenda - try The Week magazine. Start your trial subscription today –––––––––––––––––––––––––––––––
What about other types of antibody test?
While imperfect, the test made by Roche offers higher levels of accuracy than its predecessors.
“Previous tests have not been as accurate, meaning they detect antibodies against other coronaviruses such as the common cold,” says Sky News.
In March, the UK government placed orders for 17.5 million antibody tests, none of which turned out to be effective. An evaluation of their accuracy found that all were giving significant false negatives and false positives.
In April, Downing Street admitted that “no test so far has been proved to be good enough to be used”.
Why are they so hard to make?
Antibody tests “detect the body’s immune response to the infection caused by the virus rather than detecting the virus itself”, explains the US Food and Drug Administration.
Since people’s bodies react in different ways, depending on the health of their immune system and the seriousness of their infection - and since different viruses can lead to the production of similar antibodies - developing a universal test is tricky.
“To be considered accurate, devices must be able to distinguish the presence in someone’s blood of antibodies specific to this coronavirus, and also be able to identify antibodies in people who have had relatively mild strains of the disease,” says the Financial Times.
Even tests that look promising in early research can turn out to be wildly inaccurate when put into widespread use, according to Professor Paul Hunter of the University of East Anglia.
“When you don’t have enough samples you can be misled - 100 tests might look good, but after 20,000 they might not,” he says.
–––––––––––––––––––––––––––––––For a round-up of the most important stories from around the world - and a concise, refreshing and balanced take on the week’s news agenda - try The Week magazine. Start your trial subscription today –––––––––––––––––––––––––––––––
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Why Bhutan hopes tourists will put a smile back on its face
Under The Radar The 'kingdom of happiness' is facing economic problems and unprecedented emigration
By Chas Newkey-Burden, The Week UK Published
-
7 beautiful towns to visit in Switzerland during the holidays
The Week Recommends Find bliss in these charming Swiss locales that blend the traditional with the modern
By Catherine Garcia, The Week US Published
-
The Week contest: Werewolf bill
Puzzles and Quizzes
By The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
A 'transformative' gene therapy for haemophilia B
The Explainer Costly treatment that could be 'truly life-changing' for patients with rare blood disorder gets funding boost
By Julia O'Driscoll, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published